| Izrael | Turcja | Austria | |
| Podstawowe badanie kontrolne | od $300 | od $100 | od $350 |
Państwo nie płacą za usługi Bookimed. Ceny na podstawowe badanie kontrolne na stronie odpowiadają cennikowi kliniki. Płatność dokonywana jest bezpośrednio w klinice po przyjeździe. Dostępna jest płatność w ratach.
Bookimed dba o Państwa bezpieczeństwo. Współpracujemy tylko z klinikami spełniającymi wysokie międzynarodowe standardy w przeprowadzaniu podstawowego badania kontrolnego. Posiadają one wymagane licencje do obsługi pacjentów międzynarodowych na całym świecie.
Bookimed oferuje bezpłatną pomoc i wsparcie. Osobisty koordynator medyczny pozostaje w kontakcie przed, w trakcie i po podróży. Nie będą Państwo sami w innym kraju podczas procedury Podstawowe badanie kontrolne .
Lekarz jest wiodącym gastroenterologiem z ponad 30-letnim doświadczeniem w leczeniu nowotworów przewodu pokarmowego. Specjalizując się w profilaktyce, wczesnej diagnostyce i leczeniu nowotworów przewodu pokarmowego, lekarz kieruje Centrum Profilaktyki Raka w Centrum Medycznym Sourasky.<\/p>
Posiadając dyplom z medycyny ogólnej z Uniwersytetu Hebrajskiego i specjalizację z gastroenterologii z Uniwersytetu w Tel Awiwie, lekarz prowadził badania w Centrum NewYork-Presbyterian. Lekarz opublikował ponad 300 prac i jest członkiem kilku prestiżowych organizacji, w tym Amerykańskiego Stowarzyszenia Badań nad Rakiem i Europejskiego Towarzystwa Onkologii Układu Pokarmowego.<\/p>
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.
She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.
Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.